Attached files

                            For immediate release

                   Global Green, Inc. Announces Appointment of
                     Konky Sotomayor, DVM as Chief Scientist


Tallahassee,  Fla - August 15,  2012 - Global  Green,  Inc.  (OTCBB:GOGC)  today
announced the  appointment  of Konky  Sotomayor,  DVM as Chief  Scientist of the
Company. Dr. Sotomayor, the developer of Salmogenics, graduated with honors as a
Doctor in Veterinary  Medicine and Zootechny in the Veterinary  Medicine Faculty
from the State  University of Guayaquil in Ecuador.  He attended the prestigious
Lantanisbruk  Universitet in Uppsala,  Sweden,  renowned for their International
Science Program.  The program assists countries in strengthening  their domestic
research capacity within the chemical, physical and the mathematical sciences.
Dr.  Sotomayor,  a U.S.  citizen,  has  worked  in  private  laboratory-managing
research and  development  positions  since 1979 including  being a principal of
Nutritional Health Institute Laboratories,  LLC ("NHIL"). NHIL is Global Green's
research  affiliate and majority  shareholder.  He has  extensive  experience in
isolation of infectious  disease agents and  manufacturing of the  corresponding
vaccines.

 "This  appointment  recognizes  Dr.  Sotomayor's  key  role in  developing  our
flagship product,  Salmogenics. He has both a strong background and an extensive
track record in animal infectious  disease research and laboratory  diagnostics.
Dr. Sotomayor has been responsible for the discovery of novel drugs and steering
their development from basic science into clinical  development.  His experience
and R&D leadership will be instrumental as we execute our core strategy and work
to build a pipeline  of high value drug  discovery  and  development  programs,"
commented Dr. Mehran Ghazvini, Chairman and CEO.

Currently,  Dr.  Sotomayor will be responsible  for research and  development of
vaccines to expand Global  Green's  product  portfolio.  On August 8 the Company
announced it was initiating  advanced trials in quest of a salmonella-free  egg.
The purpose of the study is to  determine  how long a chicken  can be  protected
against Salmonella after it begins laying eggs.

Global Green,  Inc. is a green  pharmaceutical  company committed to identifying
technology platforms and commercializing products that contain natural organisms
that  are  not  genetically  modified,   utilizing   pharmaceutical   standards.
Salmogenics, the Company's flagship product, was developed by Nutritional Health
Institute Laboratories,  LLC, a research affiliate and majority shareholder. The
vaccine is currently in the final stage of the USDA approval  process.  For more
information, visit www.globalgreeninc.org.


Forward-Looking Statement
This press release may contain  certain  forward-looking  statements  within the
meaning of Section 27A of the  Securities  Act of 1933, as amended,  and Section
21E of the Securities Exchange Act of 1934, as amended.  Investors are cautioned
that such  forward-looking  statements  involve risks and  uncertainties,  which
include  among  others,  the  inherent  uncertainties  associated  with  smaller
reporting  companies,  including without  limitation,  other risks detailed from
time to time in the Company's  periodic  reports filed with the  Securities  and
Exchange Commission.

Contact
Pam Lagano
plagano@globalgreeninc.org
727.480.3082